Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Expansion of the 15% YoY growth drug portfolio to 60% of revenue insulates aggregate BMY cash flows against legacy patent expirations.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% EPS growth. |
| What else was confirmed? | Reported factThe company's growth portfolio of newer medicines grew 15% year-over-year and now accounts for nearly 60% of total revenue. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownNext quarter sales data for top growth portfolio medicines — Revenue breakdown between growth portfolio and legacy products in Q3 earnings |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% EPS growth.
- · The company's growth portfolio of newer medicines grew 15% year-over-year and now accounts for nearly 60% of total revenue.
- · The stock is up 17% year-to-date while continuing to trade at a valuation discount relative to pharmaceutical peers.
Public research record
Research framework · page evidenceCompleted event assessment
pipeline transition offsetting patent cliff via 15% growth portfolio expansion
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb reported Q2 revenue of $12.9 billion with 153% EPS growth. | 2026-09-21 |
| Interpretation | pipeline transition offsetting patent cliff via 15% growth portfolio expansion | BMY |
Countercase, invalidators, and sources
Growth portfolio medicines accelerate above 18% YoY, eliminating patent drag and closing peer valuation gap.
- · Next quarter sales data for top growth portfolio medicines — Revenue breakdown between growth portfolio and legacy products in Q3 earnings
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- Growth portfolio expands at 12%-15%, keeping total company revenue flat to low-single-digit positive through 2027.
- Adverse path
- Biosimilar entry against core products accelerates faster than growth pipeline commercial adoption.
- Supportive path
- Growth portfolio medicines accelerate above 18% YoY, eliminating patent drag and closing peer valuation gap.
- · Next quarter sales data for top growth portfolio medicines — Revenue breakdown between growth portfolio and legacy products in Q3 earningsnext month
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year”
Supports: BMY is up 17% YTD with Q2 $12.9B revenue and 153% EPS growth; growth portfolio accounts for ~60% of revenue, up 15% YoY